hepatitis.gif Back grey_arrow_rt.gif
 
  icon_folder.gif Recent Hepatitis Conferences icon_paper_stack.gif Articles from 2000
null.gif
  icon_star_paper.gif Recent Articles icon_person.gif Clinical Trials
 
null.gif
Co-infection with hepatitis among people with HIV is emerging as a growing problem. For people infected with HIV through needle exposure probably due to drug use, 40% or more may also have hepatitis C. The NATAP Hepatitis Section was started to raise awareness about this problem, and to provide basic education and more advanced scientific information.
 
If you have HIV you should speak to your doctor about testing for hepatitis A, B, and C. A person with hepatitis C may progress more quickly if they contract hepatitis A. If you have hepatitis C, but don't have hepatitis A, it's advisable to consider getting the hepatitis A vaccine.
 
As we report important information from key AIDS conferences, NATAP will be reporting important information presented at key hepatitis scientific conferences. They are posted below. Treatment guidelines presented by the European Association for The Study of Liver Disease at a consensus conference are posted below. NATAP will also be reporting new information from future key hepatitis conferences.
 
null.gif
med bag Ask Your Questions About HCV...
This is a truly unique opportunity for you to ask these experts your questions about Hepatitis and HCV/HIV Coinfection.
 
null.gif
  Hepatitis Information Links
 
 
HEPATITIS C and HCV/HIV COINFECTION
The lastest update on Hepatitis and HIV and HCV Coinfection. -epidemiology, the most current study results on treatment and side effects, who should be treated, and new drugs.
 
Monitor Your Liver Health in People with Chronic HCV
The Checkup, The Lab Work, Blood Platelet Count, Liver Enzyme Levels, Alpha-Fetoprotein Level, Liver Biops.
 
Current Review on Hepatitis C Virus in HIV/HCV Coinfection
Written for NATAP by Andrew Talal, M.D., and Ira Jacobson, M.D. (6/11/2001)
 
 
Basic Information on Hepatitis C
How is hepatitis C transmitted? Who should be treated? Current treatment for hepatitis C infection.
 
Hepatitis C - Frequently Asked Questions
 
Basic Facts About Hepatitis A, B, and C
How you can contract it; Functions of the liver; What can happen when hepatitis progresses--fibrosis, cirrhosis, liver cancer, liver failure
 
null.gif
CLINICAL TRIAL HOTLINE
Pegasys Clinical Trials Hotline Telephone Number People with HCV or HIV/HCV can get information about Pegasys clinical trials in their area by calling (866) GO-WINGS. Callers are connected to a live person who can refer them to clinical trial sites in their area based on their sero-status.  It is up to the caller to contact the sites to make an appointment to be screened
 
null.gif
 
  icon_star_paper.gif   Articles  
 
  1. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data - (02/03/04)
     
  2. Liver disease research funding - (02/03/04)
     
  3. Scope of Worldwide Hepatitis C Problem - (01/30/04)
     
  4. Pilot Study of the Relationship Between Histologic Progression and Hepatic Iron Concentration in Chronic Hepatitis C - (01/30/04)
     
  5. Infection with Hepatitis C Virus Genotype 4 in the United States - (01/30/04)
     
  6. Outcome of Liver Transplantation for Patients Infected by Hepatitis C, Including Those Infected by Genotype 4 - (01/28/04)
     
  7. Hepatitis C Lawsuit for Exposure to Reused Syringes in Clinic - (01/28/04)
     
  8. Low Dose PegIntron and Ribavirin in Small Study: efficacy and safety - (01/28/04)
     
  9. Schering-Plough Announces Availability of REBETOL(R) Oral Solution For Use in Treating Pediatric Hepatitis C - (01/27/04)
     
  10. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy - (01/27/04)
     
  11. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches - (01/27/04)
     
  12. HEP DART: Merimepodib (VX-497), New HCV Drug - (01/27/04)
     
  13. HEP DART: NM 283 new HCV Inhibitor - (01/26/04)
     
  14. HEP DART: Adefovir Efficacy and Resistance - (01/26/04)
     
  15. HEP DART: Combination Interferon Therapy: Infergen plus Actimmune - (01/26/04)
     
  16. HEP DART: Differences between Hepatitis B and C in the Prediction of Success of Treatment Using Early Viral Kinetics - (01/26/04)
     
  17. HEP DART: Clinical Development of Entecavir for the Treatment of Chronic Hepatitis B - (01/26/04)
     
  18. HEP DART: L-Thymidine (LdT) and Related Compounds - (01/26/04)
     
  19. HEP DART: A 12 Week Randomized Placebo-Controlled Double Blind Trial of Clevudine in Patients with Chronic Hepatitis B with Post-Treatment Follow-up for 24 weeks - (01/26/04)
     
  20. HEP DART: NM 283 new HCV Inhibitor - (01/26/04)
     
  21. Schering-Plough Announces Availability of REBETOL(R) Oral Solution For Use in Treating Pediatric Hepatitis C - (01/27/04)
     
  22. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy - (01/27/04)
     
  23. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches - (01/27/04)
     
  24. Care of patients with hepatitis C and HIV co-infection: Consensus Panel Recommendations - (01/26/04)
     
  25. Long-Term Outcomes After HCV Liver Transplant - (01/26/04)
     
  26. Liver Transplantation: Results of the first year of the new liver allocation plan - (01/26/04)
     
  27. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD: Liver Transplant Patients misdiagnosed with HCC - (01/22/04)
     
  28. Liver transplantation for hepatocellular carcinoma: The MELD impact - (01/22/04)
     
  29. Hepatotoxicity Safety Change to Label of Viramune (nevirapine) - (01/20/04)
     
  30. GB Virus Type C Coinfection in HIV-Infected African Mothers and Their Infants, KwaZulu Natal, South Africa - (01/20/04)
     
  31. GB Virus Type C: A Virus in Search of a Disease or a Role in HIV Therapy? - (01/20/04)
     
  32. PDF FORMAT - Hepatitis B: Treatment Strategies for Currently Available Drugs - (01/16/04)
     
  33. PDF FORMAT - Steatosis in Hepatitis C: What Does It Mean? - (01/16/04)
     
  34. Coley Pharmaceutical Group Initiates Phase I Clinical Trials of Actilon(TM) for Chronic Hepatitis C Infection - (01/16/04)
     
  35. Treatment considerations in patients with hepatitis C and cirrhosis - (01/15/04)
     
  36. EDITORIAL: Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? - (01/15/04)
     
  37. EDITORIAL: Rescue therapy for drug resistant hepatitis B: Another argument for combination chemotherapy? - (01/15/04)
     
  38. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B - (01/15/04)
     
  39. THE TREATMENT OF ACUTE HEPATITIS C INFECTION IN HIV-COINFECTED PATIENTS - A RETROSPECTIVE ANALYSIS OF 8 CASES IN A MULTICENTER SETTING - (01/15/04)
     
  40. DEPRESSIVE SYMPTOMS AFTER INITIATION OF INTERFERON IN HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENTS WITH CRONIC HEPATITIS C - (01/15/04)
     
  41. Global Burden of Disease (GBD) for Hepatitis C - (01/15/04)
     
  42. The Second Time Around: Retransplantation for Recurrent Hepatitis C - (01/15/04)
     
  43. High prevalence of occult hepatitis B in Baltimore injection drug users - (01/14/04)
     
  44. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection - (01/14/04)
     
  45. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection - (01/14/04)
     
  46. Viral features of lamivudine resistant hepatitis B genotypes A and D - (01/14/04)
     
  47. Reconstitution of Hepatitis B Virus Specific T Cell Responses with Treatment of Human Immunodeficiency Virus/HBV Coinfection - (01/14/04)
     
  48. Incidence of Acute Hepatitis B - United States, 1990-2002 - (01/05/04)
     
  49. FDA Approves Pegasys(R) (Peginterferon alfa-2a) Pre-filled Syringes for the Treatment of Hepatitis C - (01/14/04)
     
  50. Study highlights possible root of HCV persistence - (01/07/04)
     
  51. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression - (01/06/04)
     
  52. Pegasys Market Share - (01/06/04)
     
  53. Judge Upholds Right to HIV+Liver Transplant - (01/06/04)
     
  54. Accelerated Progression of HCV/HIV in Europe - (01/05/04)
     
  55. Liver transplantation is effective, but is it cost-effective? - (01/05/04)
     
  56. Oral feeding of hepatitis B proteins a promising treatment for chronic infection - (01/05/04)
     
  57. Glomerular filtration rate predicts seroconversion after hepatitis B vaccination - (12/29/03)
     
  58. Drugs in development hold promise for patients with HIV and HBV coinfection - (12/29/03)
     
  59. Epoetin alfa allows continuation of antiviral therapy in anemic HCV-infected patients - (12/29/03)
     
  60. Overweight & Fatty Liver Accelerates Activity and Progression of HCV - (12/29/03)
     
  61. HCV-Coinfection Is Associated with Diabetes and CD4 Decline - (12/29/03)
     
  62. Liver Adverse Events are Most Common in HIV - (12/22/03)
     
  63. Therapy for HDV! - (12/13/03)
     
  64. Sexual Activity as a Risk Factor for Hepatitis C - (12/05/03)
     
  65. Future Therapy of Hepatitis C - (12/05/03)
     
  66. Hepatitis C's time bomb - (12/01/03)
     
  67. Pretreatment Intrahepatic CD8+ Cell Count Correlates with Virological Response to Antiviral Therapy in Chronic Hepatitis C Virus Infection - (11/30/03)
     
  68. Anemia in the Treatment of Hepatitis C Virus Infection - (11/30/03)
     
  69. New NIH Liver Disease Research Branch: Action Plan For Liver Disease Research - (11/30/03)
     
  70. Hepatitis A Outbreak Associated with Green Onions at a Restaurant --- Monaca, Pennsylvania, 2003 - (11/30/03)
     
  71. EACS - Prevalence of HIV and Hepatitis B and C Among Drug Addicts in the Holy City of Amritsar, India - (11/30/03)
     
  72. Sampling variability of liver fibrosis in chronic hepatitis C - (11/30/03)
     
  73. CCR5 and Outcome of HCV Infection - (11/30/03)
     
  74. Transjugular Liver Core Biopsy: Indications, Results, and Complications - (11/30/03)
     
  75. MULTI-CENTER EVALUATION OF THE VERSANT HBV DNA 3.0 ASSAY: ASSESSMENT OF ANALYTICAL AND CLINICAL PERFORMANCE - (11/30/03)
     
  76. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients - (11/30/03)
     
  77. Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy? - (11/30/03)
     
  78. Gilead Announces Preliminary Results from 48-Week Phase III Study of Emtricitabine in Patients with Chronic Hepatitis B - (11/26/03)
     
  79. EACS - Once Daily Saquinavir/r: pharmacokinetcs (drug levels) and bioequivalence of new 500 mg Invirase tablet - (11/24/03)
     
  80. Hepatitis C Virus and Human Immunodeficiency Virus Dynamics during HCV Treatment in HCV/HIV Coinfection - (11/24/03)
     
  81. Transplantation for Patients Infected with HIV: No longer Experimental but not yet routine (editorial) - (11/24/03)
     
  82. Survival of HIV-Infected Liver Transplant Recipients - (11/24/03)
     
  83. AASLD - Treating HCV with Normal ALT with Pegasys plus Ribavirin - (11/10/03)
     
  84. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse - (11/10/03)
     
  85. Synthetic Liver - (11/10/03)
     
  86. AASLD - Rofecoxib (Vioxx) Prevents Reduction in Platelets During Pegasys Therapy for HCV: short term pilot study - (11/05/03)
     
  87. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C - (11/04/03)
     
  88. AASLD - Study Urges Doctors to Screen for Hepatitis - (11/04/03)
     
  89. AASLD - Hepatitis C in Elderly Goes Undetected and Is More Severe - (11/04/03)
     
  90. AASLD - Long Term (96 Weeks) Adefovir in HBeAg Negative Chronic Hepatitis B Results in Significant Virological, Biochemical, and Histologic Improvement - (11/04/03)
     
  91. AASLD - LONG-TERM FOLLOW-UP OF CHRONIC HEPATITIS C PATIENTS - RESPONSE TO THERAPY AND INCIDENCE OF LIVER-RELATED COMPLICATIONS - (11/04/03)
     
  92. AASLD - Effects of Lamivudine on Disease Progression and Development of Liver Cancer in Advanced Chronic Hepatitis B: a prospective double-blind placebo controlled clinical trial - (11/04/03)
     
  93. EACS - HCV Sexual Transmission --MSM & Heterosexual - (11/04/03)
     
  94. High Dose Peginterferon for Non-responders, and Naïve & Relapsers - (10/31/03)
     
  95. PROGRESSION AND TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION IN PATIENTS CO-INFECTED WITH HIV. - (10/30/03)
     
  96. EFFICACY AND TOLERABILITY OF PREEMPTIVE INTERFERON (IFN) VERSUS IFN PLUS RIBAVIRIN (RBV) TREATMENT IN HEPATITIS C VIRUS (HCV) INFECTED LIVER TRANSPLANT RECIPIENTS - (10/30/03)
     
  97. HCV Vaccines: early research - (10/30/03)
     
  98. The Immune Response to HCV: implications for HCV/HIV co-infection - (10/30/03)
     
  99. BILN 2061: HCV protease inhibitor - (10/30/03)
     
  100. SCHERING-PLOUGH REPORTS NOVEL INVESTIGATIONAL PROTEASE INHIBITOR SHOWS IN VITRO ANTIVIRAL ACTIVITY IN HEPATITIS C INFECTION - (10/29/03)
     
  101. Early Viral Kinetics Prediction of Sustained Viral Response After 1 or 4 Weeks of Peg-Interferon-a-2a (40KD) and Ribavirin Therapy (DITTO-HCV Project) - (10/29/03)
     
  102. FIBROSIS PROGRESSION IN 914 HIV-HCV CO-INFECTED PATIENTS IS STRONGLY RELATED WITH AGE: EUROPEAN COLLABORATIVE STUDY - (10/29/03)
     
  103. Fatty Liver, Liver Disease and Weight Loss - (10/28/03)
     
  104. Press Release from Vertex Pharmaceuticals - (10/28/03)
     
  105. Hepatitis C: new antiviral developments - (10/28/03)
     
  106. BENEFIT OF SUSTAINED WEIGHT LOSS AND EXERCISE IN OVERWEIGHT PATIENTS WITH LIVER DISEASE - (10/28/03)
     
  107. Press Release from Vertex Pharmaceuticals - (10/28/03)
     
  108. Hepatitis C: new antiviral developments - (10/28/03)
     
  109. Sexual Transmission of Hepatitis C Virus in Heterosexual Monogomous Couples - The HCV Partners Study - (10/27/03)
     
  110. Pegasys/Ribavirin in African Americans Showed Improved or Stabilized Fibrosis in Nonresponders - (10/27/03)
     
  111. Natural History of Fibrosis in Chronic Hepatitis C - (10/27/03)
     
  112. Intrafamilial Transmission of Hepatitis C Virus in Patients with Acute Hepatitis C: correlation with virologic and immunologic parameters - (10/27/03)
     
  113. COMPARING THE PUBLIC HEALTH BURDEN OF CHRONIC HEPATITIS C AND HIV INFECTION IN UNITED STATES - (10/27/03)
     
  114. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C - (10/24/03)
     
  115. Sexual transmission of hepatitis C and early intervention - (10/24/03)
     
  116. Iron depletion and response to interferon in chronic hepatitis C - (10/24/03)
     
  117. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse - (10/24/03)
     
  118. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy - (10/23/03)
     
  119. High HIV and Hepatitis C Rates in Massachusetts Prisons, reports the Boston Globe - (10/21/03)
     
  120. SCHERING-PLOUGH ANNOUNCES FDA APPROVAL OF PEG-INTRON REDIPEN FOR THE TREATMENT OF CHRONIC HEPATITIS C - (10/21/03)
     
  121. Those With Hepatitis C Still Face Long Odds - (10/21/03)
     
  122. New NYC Co-infection Clinic: AIDS Center at Montefiore Hospital in Bronx, New York Initiates Hepatitis C Program - (10/16/03)
     
  123. HCV Infections in Newly Freed Inmates Are a Rising Concern - (10/15/03)
     
  124. HMO Approves Kidney Transplant for HIV Patient - (10/15/03)
     
  125. New Drug for For Liver Transplantation - (10/9/03)
     
  126. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment - (10/9/03)
     
  127. Treating hepatitis C in methadone maintenance patients: an interim analysis - (10/8/03)
     
  128. ICAAC - Anti-Hepatitis B Virus (HBV) Activity of Tenofovir Disoproxil Fumarate (TDF) in Human Immunodeficiency Virus (HIV) Co-Infected Patients - (10/6/03)
     
  129. Hospitalization Rates Differ by Hepatitis C Status in an Urban HIV Cohort - (10/6/03)
     
  130. Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) - (10/6/03)
     
  131. Management of chronic hepatitis B - (10/2/03)
     
  132. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-y ligand rosiglitazone - (9/30/03)
     
  133. ART & Hepatotoxicity: Alanine aminotransferase (ALT) decrease in HIV-hepatitis C virus co-infected patients responding to antiretroviral therapy - (9/30/03)
     
  134. Transmission of Hepatitis B and C Viruses in Outpatient Settings --- New York, Oklahoma, and Nebraska, 2000-2002 - (9/29/03)
     
  135. Diabetes in HIV & HCV/HIV; prevalence, immunology - Written by Judith Aberg, MD, Washington University, St Louis, Missouri and ACTG - (9/25/03)
     
  136. Schering-Plough to Initiate First Head-to-Head Study Of Leading Hepatitis C Therapies - (9/24/03)
     
  137. ICAAC - Genetics and Virologic, Biochemical & Histologic Response to Pegylated Interferon and Ribavirin in HIV/HCV Co-infected Individuals - (9/22/03)
     
  138. Need for liver transplant in HIV-positive patients: first results of a specific survey in Italy, Project HOST - (9/19/03)
     
  139. Outcome and Management of Hepatitis C in Liver Transplant Recipients - (9/10/03)
     
  140. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B - (9/10/03)
     
  141. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C - (9/2/03)
     
  142. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in monoinfected patients with chronic hepatitis C - (9/2/03)
     
  143. Prisons plagued with Hepatitis C in Massachusetts - (9/2/03)
     
  144. HBV, HBV Vaccinations, and HAART - (8/25/03)
     
  145. Clinics Offering Free or Low Cost Hepatitis A and Hepatitis B Vaccinations In New York State - (8/20/03)
     
  146. The Impact of Hepatitis C Virus Coinfection on HIV Progression Before and After Highly Active Antiretroviral Therapy - (8/18/03)
     
  147. Coadministration of Milk Thistle and Indinavir in Healthy Subjects - (8/18/03)
     
  148. Maine: inmates with hepatitis sue for treatment - (8/13/03)
     
  149. IAS - Viral Response to Peginterferon plus Ribavirin in Co-infection - (7/24/03)
     
  150. EASL - Pegasys News: 4 year follow-up; study of treating cirrhotics; study of Peg-Intron non-responders - (7/7/03)
     
  151. EASL - Entecavir, new HBV drug, Suppresses Lamivudine Resistance - (7/7/03)
     
  152. Hepatitis C virus infection and incident type 2 diabetes - (7/7/03)
     
  153. Hepatitis Induced by Kava (Piper methysticum rhizoma) - (6/24/03)
     
  154. The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count) - (6/24/03)
     
  155. Lamivudine in Adolescents with Hepatitis B - (6/23/03)
     
  156. HEPATITIS B PRIMER - (6/23/03)
     
  157. Monitoring of viral levels during therapy of hepatitis C: early response and discontinuing HCV therapy - (6/23/03)
     
  158. Procrit for Ribavirin Induced Anemia: final study results - (6/11/03)
     
  159. Treatment options for chronic hepatitis B not responding to interferon - (6/11/03)
     
  160. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders - (6/11/03)
     
  161. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature - (6/11/03)
     
  162. Fatty Liver When ALT is Normal - (6/11/03)
     
  163. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon - (6/11/03)
     
  164. IL-12 Found Not Effective Against HCV - (6/4/03)
     
  165. DDW - Hepatitis B Report from DDW Conference: adefovir, tenofovir, clevudine - (6/4/03)
     
  166. DDW - PILOT STUDY OF PIOGLITAZONE IN NONALCOHOLIC STEATOHEPATITIS - (6/4/03)
     
  167. Extending Treatment for HCV Infection to HIV-HCV Coinfected Individuals with Psychiatric Illness and Drug Dependence - (5/28/03)
     
  168. Prevalence of Hepatitis A, Hepatitis B, and HIV Among Hepatitis C-Seropositive State Hospital Patients: Results From Oregon State Hospital - (5/28/03)
     
  169. Fat in the Liver Reduces Response to HCV Therapy - (5/27/03)
     
  170. DDW - Antioxidant-Enhanced Food Found To Reduce Ribavirin-Induced Anemia - (5/27/03)
     
  171. DDW - Preliminary Results from Comparison of PegIntron 1.0 ug/kg vs PegIntron 1.5 ug/kg - (5/27/03)
     
  172. DDW - INTERFERON GAMMA-1B FOR THE TREATMENT OF CHRONIC HEPATITIS C INFECTION - (5/27/03)
     
  173. DDW - Pegasys in Children in chronic hepatitis C: safety, efficacy and pharmacokinetics - (5/23/03)
     
  174. DDW - MICRO-NUTRIENTS AND LIVER INJURY IN THE U.S. POPULATION - (5/23/03)
     
  175. DDW - EFFECT OF SILYBUM MARIANUM ON SERUM ALT AND WELL BEING IN CHRONIC HEPATITIS C - (5/23/03)
     
  176. DDW - THE IMPACT OF BODY MASS INDEX (BMI) ON LIVER HISTOLOGY AND TREATMENT TOLERABILITY AND EFFICACY IN CHRONIC HEPATITIS C - (5/23/03)
     
  177. DDW - High Dose Censensus Interferon in Peg-IFN/Ribavirin Nonresponders - (5/22/03)
     
  178. DDW - Retreatment with PegIntron plus Ribavirin for Nonresponders & Relapsers to Prior HCV Therapy - (5/21/03)
     
  179. DDW - RACIAL DIFFERENCES IN RISK FOR LIVER CANCER IN PATIENTS WITH HEPATITIS C CIRRHOSIS: A MULTICENTER CASE-CONTROL STUDY - (5/19/03)
     
  180. Occult Hep B: Long-term histologic and virologic outcomes of acute self-limited hepatitis B - (5/9/03)
     
  181. Liver Transplantation in HIV-Infected Persons - (5/6/03)
     
  182. Hepatitis C in India - (5/5/03)
     
  183. The success of tenofovir (TNF) and didanosine (ddI) when dosed together using low-dose didanosine 250 mg - (5/2/03)
     
  184. Projecting future complications of chronic hepatitis C in the United States - (5/2/03)
     
  185. 72 weeks HCV Therapy (PegIFN/RBV): is it effective? - (5/2/03)
     
  186. Liver transplants in HIV - (5/1/03)
     
  187. FATTY LIVER: it's affect in HIV & hepatitis - (4/30/03)
     
  188. Fisting, drug use, syphilis; risk factors for hepatitis C transmission in HIV-positive gay men - (4/30/03)
     
  189. Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests? (see Editorial below by Nezam Afdahl, MD) - (4/29/03)
     
  190. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase Ira Jacobson, MD. - (4/24/03)
     
  191. PDF EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B - (4/24/03)
     
  192. Pure Protein L.L.C. Launches Hepatitis C Vaccine Discovery Project - (4/21/03)
     
  193. NEW DRUGS RESTORE IMMUNE RESPONSE BLOCKED BY HEPATITIS C VIRUS IN HUMAN CELLS - (4/21/03)
     
  194. High Rates of Viral Infections & HCV and For Risk Factors Among HIV-Infected and High-Risk HIV-Uninfected Women - (4/21/03)
     
  195. Key to Hepatitis Virus Persistence Found - (4/21/03)
     
  196. Pegylated IFN-[alpha]2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients - (4/17/03)
     
  197. Safety & Immunogenicity of Hepatitis A Vaccine in HIV-Infected Patients - (4/15/03)
     
  198. Gaps HCV Testing & Care in VA System - (4/14/03)
     
  199. Press Release from Roche - Pegasys (pegylated interferon alfa-2a) Treatment for Hepatitis B - (4/11/03)
     
  200. Press Release from Gilead Sciences - Hepsera Shows Sustained Liver Improvements in More Than 70 Percent of HBeAg-negative Chronic HBV Patients - (4/11/03)
     
  201. Study links hepatitis C to type of lymphoma
    04/9/03
     
  202. Hepatitis Updates: Lamivudine Durability in HBV Treatment; Racial Differences Regarding HCV, Iron Stores &Response to HCV Therapy; Threshold for Neutropenia in Interferon Therapy; ALT in Predicting Liver Fibrosis; RNA Interference in Discovering Drugs for HBV. - (4/9/03)
     
  203. Outbreak of Hepatitis A among Men Who Have Sex with Men: Implications for Hepatitis A Vaccination Strategies - (4/7/03)
     
  204. Hepatitis C Virus Transmission from an Antibody-Negative Organ and Tissue Donor --- United States, 2000--2002 - (4/4/03)
     
  205. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients - (4/3/03)
     
  206. HCV in Semen - (3/26/03)
     
  207. Hepatitis C Virus in Patients With HIV Infection and Lipodystrophy - (3/12/03)
     
  208. Severe Hepatotoxicity During Combination Antiretroviral Treatment: Incidence, Liver Histology, and Outcome - (3/12/03)
     
  209. Impaired Insulin Sensitivity in HIV-infected Individuals is Associated with Higher Hepatic Lipid Content and Visceral Adiposity - (3/10/03)
     
  210. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response - (3/11/03)
     
  211. Retro - Evidence Suggesting Mitochondrial Toxicity in HIV/HCV Co-infected Patients Receiving Ribavirin and Didanosine - (3/10/03)
     
  212. Retro - Hepatitis C & B Report from Retrovirus Nancy Shulman, MD, Stanford University- (3/6/03)
     
  213. Perinatal Hepatitis C Virus Transmission: Role of Human Immunodeficiency Virus Infection and Injection Drug Use - Gregory L. Armstrong, Joseph F. Perz, and Miriam J. Alter Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia - (2/28/03)
     
  214. Retro - High Indinavir Plasma Concentrations in HIV-1 Patients Co-infected with Hepatitis B or C Virus Receiving Indinavir and Ritonavir Low Dosages: A GENOPHAR Substudy - (2/24/03)
     
  215. Retro - Predictive Value of Early Virological Response (12 Weeks) to Pegylated Interferon plus Ribavirin in HIV-HCV Co-infected Patients - (2/24/03)
     
  216. SCHERING-PLOUGH IN LICENSING AGREEMENT WITH THREE RIVERS PHARMACEUTICALS TO RESOLVE U.S. RIBAVIRIN PATENT DISPUTE(2/21/03)
     
  217. Peg-Intron Access Assurance Programs Ends; Patient Assistance Program (2/20/03)
     
  218. HIV Accelerates HCV, Spanish study finds (2/11/03)
     
  219. Should Acute HCV Be Treated? (2/11/03)
     
  220. Spaniah practice guidelines for the management of HIV and Hepatitis co-infections (2000-2002) from the GESIDA Consensus Conferences. (2/6/03)
     
  221. Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings (2/6/03)
     
  222. Therapy with Reduced Dose of Pegylated Interferon Plus Ribavirin in HCV & HIV Coinfected Patients (2/6/03)
     
  223. Depression More Likely to Strike Women Receiving Interferon for Hepatitis (2/6/03)
     
  224. Effect of GB Virus C Coinfection on Response to Antiretroviral Treatment in Human Immunodeficiency Virus Infected Patients (2/6/03)
     
  225. Increased Risk of Mother-to-Infant Transmission of Hepatitis C Virus by Intrapartum Infantile Exposure to Maternal Blood (2/6/03)
     
  226. Hepatitis E in Developed Countries (2/4/03)
     
  227. Influence of Coinfection with Hepatitis C Virus on Morbidity and Mortality Due to Human Immunodeficiency Virus Infection in the Era of Highly Active Antiretroviral Therapy (1/31/03)
     
  228. CDC Hepatitis C Coordinators Conference: brief selected highlights. Remember the Alamo. (1/30/03)
     
  229. Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings (1/27/03)
     
  230. Fatty Liver Disease, ALT, & Overweight (1/27/03)
     
  231. Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibility for Interferon Treatment (1/24/03)
     
  232. The Clinical Spectrum of Hepatitis C Virus in HIV Coinfection (1/17/03)
     
  233. ROCHE ANNOUNCES PRICE ON RIBAVIRIN (1/14/03)
     
  234. Roche Dramatically Reduces Cost of Combination Therapy for Millions of Americans Chronically Infected with Hepatitis C - Press Release from Roche (1/14/03)
     
  235. Hepatitis C treatment may cost N.J. millions - By Mark Fazlollah and Jennifer Lin Philadelpha Inquirer, Jan 12 2003 (1/14/03)
     
  236. Hepatology Highlights - Hepatology, January 2003, Volume 37, Number 1 Harvey J. Alter, Viral Hepatitis Editor - (1/8/03)
     
  237. Is HCV Curable? - Reported by Jules Levin - (1/8/03)
     
  238. Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals - (1/7/03)
     
  239. HCV Protease Inhibitors: Vertex VX-950 clinical trial in 2003 - (1/3/03)
     
  240. Hepatitis C Protease Inhibitors - (1/3/03)
     
  241. Subclinical impairment of brain function in chronic hepatitis C infection - (12/27/02)
     
  242. VA Offers New Treatment for Veterans with Hepatitis C - (12/27/02)
     
  243. High Rates of HCV, HIV/HCV Coinfection, and Alcohol Abuse in NYC Veterans - (12/27/02)
     
  244. Prevalence of Hepatitis C Virus Infection and Risk for Hepatocellular Carcinoma and Non-Hodgkin Lymphoma in AIDS - (12/19/02)
     
  245. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals - (12/16/02)
     
  246. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) - (12/16/02)
     
  247. Does HCV Replicate Outside The Liver and It's Significance? - (12/12/02)
     
  248. Does Bleach Disinfection of Syringes Protect Against Hepatitis C Infection Among Young Adult Injection Drug Users? - (12/12/02)
     
  249. The Hepatitis D Virus - (12/06/02)
     
  250. Lamivudine for Chronic Delta Hepatitis - (12/06/02)
     
  251. PDF FORMAT - NATIONAL INSTITUTES OF HEALTH CONSENSUS DEVELOPMENT CONFERENCE FINAL STATEMENT Management of Hepatitis C:2002; June 10 -12,2002 - (12/02/02)
     
  252. Jocelyn Elders Speaks Out On Harm Reduction & Clean Needles: an answer to stemming tide of HIV and HCV - (12/02/02)
     
  253. HCV in HIV Coinfection and in IVDUs - (11/26/02)
     
  254. Tenofovir for HBV in HIV/HBV Coinfection - (11/25/02)
     
  255. Vaccine Hepatitis C - BBC NEWS WORLD ADDITION - (11/21/02)
     
  256. AASLD - HCV Viral Kinetics and Early Response Predicting Sustained Response - (11/19/02)
     
  257. AASLD - IVDUs, Depression & Mental/Emotional Issues in HCV Therapy Can Be Successfully Addressed - (11/19/02)
     
  258. AASLD - Treatment for Hepatitis B Looks Promising - (11/19/02)
     
  259. Comparison of Methodologies for Quantification of Hepatitis C Virus (HCV) RNA in Patients Coinfected with HCV and Human Immunodeficiency Virus - Clinical Infectious Diseases 2002;35:482-487 - (11/13/02)
     
  260. AASLD - Twice Weekly Injections of PegIntron - (11/13/02)
     
  261. AASLD - Pegasys plus Ribavirin in African-Americans - (11/13/02)
     
  262. AASLD - Hepatitis C Found In Cerebrospinal Fluid - (11/13/02)
     
  263. AASLD - Orally available Hepatitis C Virus (HCV) Protease Inhibitor (BILN 2061, Boehringer Ingelheim Pharma) Demonstrates Potent Anti-viral Activity in Persons Infected with HCV Genotype 1 - Written by Mark Sulkowski, MD, Johns Hopkin University School of Medicine - (11/8/02)
     
  264. AASLD - Ist HCV Protease Inhibitor: 2nd study presented at AASLD - (11/8/02)
     
  265. AASLD - Hard to Treat Patients: African Americans and previous nonresponders - (11/7/02)
     
  266. AASLD - Predictive Value of Early Virologic Response - (11/7/02)
     
  267. AASLD - Retreatment of Nonresponders & Relapsers and Maintenance Therapy - (11/7/02)
     
  268. AASLD - 1st HCV protease Inhibitor: effective over 2-day study - (11/7/02)
     
  269. AASLD - 1st HCV protease Inhibitor: effective over 2-day study - (11-5-02)
     
  270. AASLD - Does HIV Accelerate HCV Progression? - (11-5-02)
     
  271. AASLD - Liver Transplantation in HIV and HCV Coinfected Patients - (11-5-02)
     
  272. AASLD - Liver Transplantation in HIV and HCV Coinfected Patients - (11/3/02)
     
  273. AASLD - EPOETIN ALFA (PROCRIT) ONCE WEEKLY MAINTAINS RIBAVIRIN DOSE IN HEPATITIS C VIRUS (HCV)-INFECTED PATIENTS TREATED WITH COMBINATION THERAPY: interim results - (11/3/02)
     
  274. AASLD - NEW HCV DRUGS IN EARLY DEVELOPMENT - (11/3/02)
     
  275. AASLD - HCV Viral Kinetics During Therapy - (11/3/02)
     
  276. Medicaid and ADAP Access to Peginterferon and ribavirin - (11/1/02)
     
  277. CIRRHOSIS: advanced liver disease - (10/30/02)
     
  278. Trends in hepatitis C and HIV infection among inmates entering prisons in California, 1994 versus 1999 - (10/30/02)
     
  279. End Stage Liver Disease Leading Cause of Death in HCV/HIV Coinfected in France; 46% Had Cirrhosis; 37% had >200 Cd4s & <500 copies/ml viral load - (10/30/02)
     
  280. Abnormal lipids & GGT May Predict Poor Outcome in HCV/HIV Coinfection - (10/29/02)
     
  281. Adherence in HCV Therapy - (10/24/02)
     
  282. Risk For Hepatitis C Transmission in Hospital/Clinic Setting: use of multidose medication vials- HCV transmission risk and management of acute HCV in hospital settings - (10/21/02)
     
  283. My New Liver - By Larry Kramer - (10/21/02)
     
  284. Organ Transplants: We Must Have Presumed Consent - By Larry Kramer - (10/21/02)
     
  285. Hep C Outbreak at Clinic The Associated Press - (10/17/02)
     
  286. Hepatitis Cases May Be Linked to Needles at Clinic - By BARRY MEIER - (10/17/02)
     
  287. The Risk of Eating Raw Oysters & Clams - (10/15/02)
     
  288. ICCAC - Resistance to Atazanavir - (10/7/02)
     
  289. ICCAC - Hepatitis C: Can You Replace the Liver Biopsy With Less Invasive Tests - (10/7/02)
     
  290. ICCAC - Tenofovir in the Treatment of Individuals Co-Infected with HIV and Hepatitis B Abstract - (10/7/02)
     
  291. ICCAC - PegIntron plus Ribavirin vs Interferon plus Rinavirin in HCV/HIV Coinfected Patients: preliminary week 48 results - (10/7/02)
     
  292. ICCAC - Kaletra + Amprenavir & Boosted Ritonavir in PI Experiened Patients - (10/7/02)
     
  293. ICCAC - Integrase Inhibitors Advancing: S-1360 & metabolic abormalities - (10/1/02)
     
  294. ICCAC - T-20 and T-1249 - (10/1/02)
     
  295. Pegasys + Ribavirin: study results published - (9/27/02)
     
  296. HEPATITIS B PRIMER - (9/24/02)
     
  297. FDA Approves Adefovir for Chronic Hepatitis B - (9/23/02)
     
  298. One in ten veterans in New York City area infected with HCV
    09/19/02
     
  299. Roche's ribavirin Copegus available in all EU Countries within months - (9/18/02)
     
  300. Viral load in HCV RNA-positive pregnant women - (9/18/02)
     
  301. Hep C & Pregnancy: risks for transmission - (9/18/02)
     
  302. Organ (Liver) Transplants - (9/18/02)
     
  303. Does HAART harm the Liver? NNRTI-related or -unrelated hepatotoxicity? - (9/13/02)
     
  304. Hepatitis Online Newsletter - (9/13/02)
     
  305. Alcohol and mitochondria: A dysfunctional relationship - (9/10/02)
     
  306. Frequency of the HIV-protective CC chemokine receptor 5-32/32 genotype is increased in hepatitis C - (9/10/02)
     
  307. Psychiatric disorders among veterans with hepatitis C infection - (9/10/02)
     
  308. Interferon therapy prolonged life expectancy among chronic hepatitis C patients: for both responders & perhaps nonresponders - (9/10/02)
     
  309. HCV in HIV-Coinfection: ADAP, Access, Treatment Costs - (9/09/02)
     
  310. Injection Drug Use Facilitates Hepatitis C Virus Infection of Peripheral Blood Mononuclear Cells - (9/09/02)
     
  311. Hepatitis C and Progression of HIV Disease - (9/06/02)
     
  312. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection - (9/06/02)
     
  313. Liver transplantation for patients on methadone maintenance - (9/06/02)
     
  314. Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol - (9/03/02)
     
  315. Opportunities for prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users - (9/03/02)
     
  316. Virahep-c - (9/03/02)
     
  317. HEPP (HIV & Hepatitis Education Prision Project) Subject: HCV and HCV in Prisions - Report Aug/Sept 2002 Vol. 5 Issue 8&9 - PDF Format - (9/03/02)
     
  318. A Case For Sexual Transmission of HCV: is there a higher risk among men who have sex with men? - (8/30/02)
     
  319. National Institutes of Health Consensus Development Conference Statement - FINAL STATEMENT - (8/30/02)
     
  320. Liver & Kidney Transplants in HIV: selected HIV-related abstracts from Intl Congress on Transplantation Conference, Aug 25-30, 2002, Miami, FL. - (8/30/02)
     
  321. Liver & Lidney Transplants in HIV: New Research at Intl Congress on Transplantation Society - (8/30/02)
     
  322. Hepatitis C May Cause Erectile Dysfunction
    08/14/02
     
  323. Erectile Dysfunction and Hepatitis C Virus Infection - (8/14/02)
     
  324. Hepatitis C Antiviral Resistance in African-Americans (only for HIV- patients) - (8/9/02)
     
  325. Barcelona - Study Finds Increase in AST After starting ART Increases Risk For death More Than Having HCV - (8/5/02)
     
  326. Hepatitis Highlights from Intl AIDS Conference Barcelona - (8/1/02)
     
  327. Barcelona - FDA GRANTS PRIORITY REVIEW TO PEGASYS (peginterferon alfa-2a) AND RIBAVIRIN COMBINATION FOR TREATMENT OF HEPATITIS C - (7/16/02)
     
  328. Barcelona - Does Liver Disease Improve for HCV Therapy Nonresponders? - (7/15/02)
     
  329. DDW - Review of Oral Presentations and Posters presented at DDW May 19-20 Written by Written by Andrew Talal, MD, NY Hospital-Cornell Medical College, Dept of GI & Hepatology - (7/9/02)
     
  330. Barcelona - PegIntron + Ribavirin in HIV/HCV Coinfected Patients - (7/11/02)
     
  331. Barcelona - New HIV Drugs / Hep C: quicker HCV progression nin coinfection; sumptomatic hyperlactatemia in coinfected patients taking RBV; PegIntron/RBV in coinfected - (7/8/02)
     
  332. Hep C Online News: recently reported studies in HCV - (06/28/02)
     
  333. Latest update on: HEPATITIS C and HCV/HIV COINFECTION - (06/24/02)
     
  334. Acute hepatitis C: To treat or not to treat? - (06/18/02)
     
  335. Hep C Patients with Normal ALT, treatment or not? - (06/17/02)
     
  336. Diagnosing and Monitoring Tests in HCV For Patients: viral load, biopsy - (6/17/02)
     
  337. Re-treatment of Patients with HCV Excerpted from NIH HCV Consensus Development Conference Draft Report (June 2002) - (6/17/02)
     
  338. Treatment in Special Patient populations: HIV, IVDUs, children, alcohol users, advanced liver disease excerpt from NIH HCV Consensus Development Conference draft report - (6/17/02)
     
  339. Recommendations to Prevent HCV Transmission from NIH HCV Consensus Conference Panel draft report (june 2002) - (6/17/02)
     
  340. NATURAL HISTORY OF COMPENSATED CIRRHOSIS - (06/17/02)
     
  341. TRANSPLANT RECIPIENTS FAILING LAMIVUDINE THERAPY FOR CHRONIC HEPATITIS B INFECTION - (06/17/02)
     
  342. NIH Panel Recommends Expand Access for HCV Therapy to HIV, IVDUs, children - (6/14/02)
     
  343. PegIntron plus Ribavirin in 65 HCV/HIV Coinfected Patients - (06/14/02)
     
  344. Quality of Life of Pegasys+Ribavirin vs Interferon+Ribavirin (48 Week Results) - (06/14/02)
     
  345. SELECTED HIGHLIGHTS FROM THE DRAFT NIH HCV CONSENSUS STATEMENT - (06/13/02)
     
  346. Report from NIH HCV - Management of Hep C in HIV-infected Persons in the USA - (06/13/02)
     
  347. Report from Day 3 at NIH HCV Consensus Conference - (06/12/02)
     
  348. NIH HCV Conference Report - Report 3, June 11 - (06/11/02)
     
  349. NIH HCV Conference Report - Part 2 Afternoon Session June 10 (No surprises today) - (06/10/02)
     
  350. NIH HCV Conference Report - Report 1, Morning Session, June 10 - (06/10/02)
     
  351. HEPATITIS CASES IN BOSTON SURGE OFFICIALS CITE WIDER TESTING - (06/07/02)
     
  352. Women and HCV - (06/03/02)
     
  353. HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C - (05/23/02)
     
  354. THE IMPACT OF ALCOHOL AND INTERFERON TREATMENT ON THE CLINICAL OUTCOME OF HEPATITIS C (HCV)-RELATED CIRRHOSIS - (05/23/02)
     
  355. Fatigue, HCV/HIV Coinfection, Transmission, Disease Progression & Interferon Written by David Bernstein, MD, Chief of Hepatology at North Shore Hospital, Manhasset, NY - (5/23/02)
     
  356. HCV /HIV Nonresponders Experience Improved Disease Progression - (5/23/02)
     
  357. PEGINTERFERON ALPHA-2A ALONE OR IN COMBINATION WITH RIBAVIRIN ENHANCES RESTORATION OF THE HCV SPECIFIC T CELL RESPONSES IN PATIENTS WITH CHRONIC HEPATITIS C - (5/23/02)
     
  358. BONE LOSS in HCV - (5/23/02)
     
  359. HEPATITIS C - TRANSMISSION BY TOOTHBRUSHES: A MYTH OR A REAL POSSIBILITY? - (5/22/02)
     
  360. Key Selected Highlights From Day One Hepatitis C Oral Presentations - (5/21/02)
     
  361. Pegylated Interferon (PegIntron) and Ribavirin for Hep C Patients who were Previous Nonresponders - (5-21-02)
     
  362. Prediction of Early Virologic Response to Pegasys plus Ribavirin in Patients with Genotype 1: can 24 hour viral load response predict 72 week outcome - (5/21/02)
     
  363. PegIntron and Ribavirin in African-Americans and Caucasians; preliminary report - (5/21/02)
     
  364. HCV Therapy in Methadone Maintenance - (5/21/02)
     
  365. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection - (05/14/02)
     
  366. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C (with editorial)  PDF - (05/09/02)
     
  367. New study: HCV and racial disparities in response to antiviral therapy - (05/09/02)
     
  368. DIAGNOSTIC VALUE OF LIVER BIOPSY IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION (04/26/02)
     
  369. DIABETES IN HCV - (04/26/02)
     
  370. Bone Mineral Density Loss in HCV - (04/26/02)
     
  371. Hepatitis B Report: adefovir; Pegasys - April 19, 2002
     
  372. Amantadine Triple Therapy: interferon/ribavirin - April 19, 2002
     
  373. Pegasys + Ribavirin: 24 vs 48 weeks; 800 vs 1000/1200 ribavirin - April 18, 2002
     
  374. Neuropsychological Impairment in Patients with Chronic Hepatitis C (04/18/02)
     
  375. Impact of Hepatitis Coinfection on Health & Survival (04/4/02)
     
  376. Highlights of Treatment for HBV or HCV Coinfection Written for NATAP by Raymond Chung, MD, Director of Liver Transplantation Program, Massachusetts General Hospital (03/26/02)
     
  377. Hepatitis B and C Coinfection Report - Wriiten by Nancy Shulman, MD, Stanford University - (03/14/02)
     
  378. Expanded Access Available for New Hepatitis B Drug- Adefovir - (03/14/02)
     
  379. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy - (03/14/02)
     
  380. Hepatitis B Report : More Acute HBV Infection in HIV-Patients; 3TC Protective; 14% Vaccinated - (03/11/02)
     
  381. The HCV and HIV Coinfected Patient: What Have We Learned About Pathophysiology? Andrew H. Talal, MD, MPH, P. Wilfredo Canchis, MD, and Ira M. Jacobson, MD; Weill College of Medicine, Cornell university, NYC
    (02/22/02)
     
  382. Study Reports Hepatitis C Impairs Cognitive Functioning: memory, concentration, depression
    (02/07/02)
     
  383. New HCV Drug in Phase I
    Idun Pharmaceuticals' Clinical Trial Demonstrates Safety Of Liver Disease Drug - Phase I Trial Demonstrates Safety and Opens the Door To Treat Multiple Liver Diseases -

    (02/04/02)
     
  384. Bone Loss in Liver Disease
    (02/04/02)
     
  385. ACT II; GAY AIDS ACTIVIST AND LIVER TRANSPLANT RECIPIENT TURNS ATTENTION TO RAISING AWARENESS OF NEED FOR ORGAN DONATION CHRISTOPHER SNOWBECK, POST-GAZETTE STAFF WRITER
    (01/31/02)
     
  386. New HCV Drug in Phase 1 - XTL Biopharmaceuticals Announces Positive Phase Ia Clinical Trial Results for Hepatitis C
    (01/25/02)
     
  387. Overview of Pharmacokinetic Properties of Pegasys
    (01/14/02)
     
  388. How Does Interferon Work in Your Body
    (01/14/02)
     
  389. Hepatitis C Protease Inhibitors
    (01/09/02)
     
  390. Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment.
    (01/09/02)
     
  391. Long-term efficacy of combination therapy with interferon-2b and ribavirin for severe chronic hepatitis C in HIV-infected patients
    (12/27/01)
     
  392. Is the Natural History of Hepatitis C Virus Carriers With Normal Aminotransferase Really Benign?   (12/17/01)
     
  393. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study  PDF (12/10/01)
     

IMPACT OF PREGNANCIES, ORAL CONTRACEPTION AND MENOPAUSE ON LIVER FIBROSIS PROGRESSION IN WOMEN WITH CHRONIC HEPATITIS C
(12/3/01)

HCV Therapy Adherence; New drugs
(12/3/01)

Treatment of Acute Hepatitis C with Interferon Alfa-2b
(10/01/01)

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study
(10/01/01)

Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C
(9/28/01)

Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers
(9/28/01)

Factors Affecting Liver Fibrosis in Human Immunodeficiency Virus and Hepatitis C Virus Coinfected Patients: Impact of Protease Inhibitor Therapy
(9/24/01)

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
(9/240/01)

Mother-to-Infant Transmission of Hepatitis C Virus
with full version in PDF format
(9/14/01)

A Randomized, Double-Blind Trial Comparing Pegylated Interferon Alfa-2b to Interferon Alfa-2b as Initial Treatment for Chronic Hepatitis C
with full version in PDF format
(9/13/01)

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection
(9/10/01)

Viral Load at Week 12 and Reduction in Viral Load in First 12 weeks of Therapy is Useful in Predicting Response
with complete report in PDF

(9/6/01)

Development of Pegylated Interferons for the Treatment of Chronic Hepatitis C
in PDF format only
(9/4/01)

Can Cirrhotics Achieve a Histologic Response?
with PDF of full article
(9/4/01)

Can HCV Be Cured: more on longterm outcomes in Sustained Virologic Responders
(8/16/01)

Hepatitis B Update
      Adefovir for HBV ...>
      Safety & Adefovir Resistance ...>
      
Adefovir 30mg Dose: safety concerns ...>
      Adefovir plus HAART shows benefits for HIV/HBV co-infected patients ...>
      3TC Resistance: incidence in HBV and HIV/HBV treatment ...>
      Adefovir 10 mg Added to HAART with 3TC HBV Resistance ...>
      Week 48 Interim Results ...>
      Entecavir: new Hepatitis B drug in early research ...>
      L-DT: New Hepatitis B Drug ...>
(8/5/01)

HIV Patients Getting More Transplants
    
By DENISE LAVOIE, Associated Press Writer
(8/5/01
)
Evidence for a cerebral effect of the hepatitis C virus
(8/5/01)
10-Year Follow-up After Interferon- Therapy for Chronic Hepatitis C: all 5 patients with sustained viral response remained HCV-RNA negative by liver biopsy
(8/3/01)

Predictive Value of Alt Levels On Histological Findings In Chronic Hepatitis C: A European Collaborative Study
(8/2/01)

Independent Predictors of Severe Liver Fibrosis in Chronic Hepatitis C
(8/2/01)

HCV & Pregnancy, risk factors for transmission: breastfeeding, c-section, use of forceps in delivery
(8/1/01)
Impact of Hiv Infection On Health-Related Quality of Life In Patients with Chronic Hepatitis C: An Unexpected Finding
(8/1/01)
High Dose Induction Therapy With Consensus Interferon Followed By Combination Therapy With Ribavirin For Treatment-Naive Hepatitis C Patients
(8/1/01)
Diet and Hepatitis C
     Written for NATAP by Jocelyn Rodriguez

(8/1/01)

Does HAART Affect Liver Disease Progression in HCV/HIV Coinfected Patients?
(7/11/01)

Assessment of Fatigue and Psychologic Disturbances in Patients with Hepatitis C Virus Infection
with PDF of full article
(7/9/01)

Patient's Ability to Mount an Immune Response Appears Associated with Response to HCV Therapy
(7/9/01)

Preliminary study Results Show HCV in Blood Reflects HCV in Liver Cells
(7/9/01)

Transplantation in HIV-positive Patients?
     Latest update from University of Pittsburgh, from John Fung, MD, PhD, 06/28/01
(7/9/2001)

Study of Treatment for HCV Following Recurrence of HCV After Liver Transplant
(7/9/2001)

Predicting Response to HCV Therapy After One Day of Inteferon
(7/9/2001)

Two Studies Find Benefit in Treating HCV During Acute Infection
(7/9/2001)

Hepatitis C: current & future treatment, progress & challenges
(7/9/2001)

Molecular Biology of Hepatitis C
Full Article in PDF format...>
     written by Kenneth Drazan, MD
(6/25/2001)

The impact of HIV infection on the hepatitis B (HBV)-specific CD8 response in HIV/HBV coinfected patients
(5/14/2001)

Sexual Risk of HCV Transmission
Hepatitis C virus among high and low risk pregnant women in Dundee: unlinked anonymous testing: another study suggesting sexual risk of transmitting HCV
(5/09/2001)

Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus
     European Paediatric Hepatitis C Virus Network

(5/08/2001)

Amantadine+Interferon/Ribivarin in Interferon Non-Responders
Randomized, Controlled Trial with Interferon-Alpha  (IFN-ALPHA) Combined with Ribavirin, With and Without Amantadine Sulfate in Primary IFN-Alpha Nonresponsive Patients with Chronic Hepatitis C
(5/07/2001)

Durability of Sustained Virologic Response: 3 year follow-up
Durability of Viral Response to Interferon Ribavirin Combination in Patients with Chronic Hepatitis C: of 311 SVRs, during 3 years follow-up 7 patients had late relapse

(5/07/2001)

Entecavir: new Hepatitis B drug in early research
A Phase II Study of Entecavir vs. Lamivudine in Adulst with Chronic Hepatitis B
(5/07/01)

Assessment of Fatigue and Psychologic Disturbances in Patients with Hepatitis C Virus Infection
      Gastroenterol, May 2001

(5/07/2001)

New Ribivarin in Research (ICN 17261)
(5/07/2001)

More on Amantadine in Combination with Interferon and Ribivarin
(5/06/2001)

Highlights from
The 36th Annual Meeting of EASL
(European Association for the Study of the Liver) April 18-22, 2001, Prague, Czech Republic

    
Written for NATAP by Harvey S. Bartnof, MD
(4/21/2001)

Maintenance interferon for chronic hepatitis C: More issues than answers?
     
Written by Gregory T. Everson, M.D.
(Full  PDF of this article)
(4/30/2001)

Virologic Response To Pegasys With Genotype 4 in Small Study Group
(4/10/2001)

Human Genome Sciences To Test New Delivery Method for HCV Interferon
     By Scott Henley of the Wall St. Journal / Help
(3/25/2001)

Check Your Thyroid Function Before & During Interferon Therapy: Interferon-alpha-induced disorders of thyroid function. A retrospective analysis of the literature and personal experiences
(3/11/2001)

Hepatitis Virus Infections, Including HIV Co-Infection Part III:
6%-20% of HCV/HIV coinfected found to have false HCV negativity, may be related to low CD4 count; HBV false negatives also seen
     
By Harvey S. Bartnof, MD 
(3/01/2001)

This report finds high HCV viral load increases risk of transmission of HCV from mother to newborn
HCV Viremia at Delivery a Risk Factor for Mother-to-Infant Transmission
WESTPORT, CT (Reuters Health)

(2/26/2001)

NOTICE TO ADVOCACY GROUPS:
Pegasys HCV/HIV Coinfection Study for HCV Interferon & Ribivarin Naive
You may be eligible to participate in this study if you:
     Are coinfected with HCV (hepatitis C virus) and HIV
     Are 18 years or older
(2/7/2001)

Interferon Appears to Slow Progression, cancer & death in this Japanese Study of Patients with Compensated Cirrhosis
Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis
     with  PDF  of entire article
(1/31/2001)

Biopsy Is Required To Evaluate Liver Disease Severity and Decide When To Begin Therapy
The Histologic Spectrum of Chronic Hepatitis C in Patients with Repeatedly Normal ALT (Alanine Aminotransferase): Does Liver Biopsy Make a Difference?
(1/28/2001)

Pharmacokinetics on Two Pegylated Interferons Reported at AASLD 1999 (2/23/2000)

Peg Intron FDA Approved
First Pegylated Interferon Approved for Marketing in the United States
Schering Press Release

FDA Approves Hepatitis C Therapy: Peg Intron Pricing
     By THE ASSOCIATED PRESS

(01/24/2001)

 Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection: women 39 years or less of age respond better to HCV treatment than men and women older than 40 years
     Department of General Medicine, Kyushu University Hospital, 
Fukuoka, Japan.

     Archives of Internal Medicine.  158(2):177-81, 1998 Jan 26
(01/24/2001)

AASLD Report On HCV Therapy Toxicities
H
emoglobin Decreases from Combination HCV Therapy including Ribibarin  (01/08/2001)

Three Factors Predictive of ALT > 5 times Upper Limit of Normal: HBV, HCV and elevated baseline ALT; 45% with HBV & 33% with HCV had ALT > 5 times Upper limit of Normal (01/03/2001)

Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature (01/02/2001)

Fatigue Affecting People With Liver Disease  (01/01/2001)

 

 
  icon_folder.gif   Conferences  
 

Reports from the
AASLD Conference:
New HCV drugs, new ultrasensitive HCV viral load test, preliminary data on pegylated interferon in HCV/HIV coinfected patients, response to pegylated interferon in previous non-responders to Rebetron
(11/09/2001)

Reports from the
AASLD Conference:
New Therapeutic Strategies for Hepatitis C
(6/15/2001)

Highlights from
The 36th Annual Meeting of EASL 
(European Association for the Study of the Liver)
    
Written for NATAP by Harvey S. Bartnof, MD Staff Physician at AVERI, AIDS Virus Education and Research Institute in San Francisco, CA.
(4/21/2001)